Stoky
Back to explore
N
NoahListening
A
AshListening
0:00 / 0:00I. Business Overview and Strategy
RVTY logo

Revvity Revenue Drops 17% Post-Divestiture, Focuses on Core Health Sciences

RVTY10-KFiling Date: 2/27/2024
Revvity, Inc.
Description

What this story covers

Revvity, Inc. reported 2 point 75 billion dollars revenue in 2023, down 17 percent from COVID normalization and divestiture of non-core businesses for 2 point 13 billion dollars cash. Life Sciences stable at 1 point 29 billion dollars; Diagnostics fell 28 percent. Operating income resilient, liquidity strong with 913 million dollars cash. Strategy emphasizes innovation in life sciences and diagnostics amid risks like competition and regulations.

Story snapshot

CompanyRevvity, Inc.
TickerRVTY
VariantStandard detailed
Duration10:37
Filing type10-K
PeriodAnnual 2023
IndustryHealthcare & Pharmaceuticals
Accession0000031791-24-000004

Full Story Script

Content not available for this story.

Ask Noah

Question the story, source filings, and key financial signals.

Sign in to chat with Noah

Ask questions about revenue, margins, risk factors, filings and more. Noah uses retrieval-augmented analysis over raw financial disclosures.

Sign in